Tizeg 50 mg Powder for solution for infusion
PDF Leaflet Revision Date: 31 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Severe life-threatening infections in adults.
Dosage (summary)
Initial 100 mg IV, then 50 mg every 12 hours for 5-14 days.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Warfarin
- Calcineurin inhibitors
- Oral contraceptives
Contraindications
- Hypersensitivity to tigecycline
- Pregnancy
Common side effects
- Nausea
- Vomiting
- Dizziness
- Abdominal pain
Counselling Points
- Monitor for superinfection
- Avoid in severe hepatic impairment
- Report any signs of pancreatitis
Serious warnings
- Higher mortality in some infections
- Anaphylaxis
- Hepatic failure
Important Disclaimer
The Tizeg 50 mg Powder for solution for infusion professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
